AZENTA, INC. (AZTA) FY2026 YTD Q3 Statement of Cash Flows
2025-10-01 to 2026-06-30
Statement of Cash Flows
2025-10-01 to 2026-06-30
Swipe to see the full flow
Chart details
AZENTA, INC. cash flow reconciliation, Oct 1, 2025 through Jun 30, 2026
Cash flows for Oct 1, 2025 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Sep 30, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.
- Beginning cash on Sep 30, 2025
- 296,685,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
- Operating activities
- 35,805,000 US dollars. Net cash provided.
- Net loss
- negative 173,774,000 US dollars
- Stock-based compensation
- 15,232,000 US dollars
- Inventory write-downs and other non-cash items
- 1,301,000 US dollars
- Loss on assets held for sale
- 9,491,000 US dollars
- Depreciation and amortization
- 41,230,000 US dollars
- Other assets and liabilities
- 9,540,000 US dollars
- Accrued restructuring costs
- 26,000 US dollars
- Accrued compensation and tax withholdings
- negative 3,816,000 US dollars
- Accrued warranty and retrofit costs
- 84,000 US dollars
- Deferred revenue
- 1,986,000 US dollars
- Accounts payable
- negative 655,000 US dollars
- Inventories
- negative 9,501,000 US dollars
- Accounts receivable
- 4,073,000 US dollars
- Loss on disposals of property, plant and equipment
- 14,000 US dollars
- Deferred income taxes
- negative 3,563,000 US dollars
- Amortization and accretion on marketable securities
- negative 1,088,000 US dollars
- Non-cash gain from settlement of preexisting contractual relationship
- negative 3,858,000 US dollars
- Impairment of goodwill and intangible assets
- 149,083,000 US dollars
- Investing activities
- negative 73,253,000 US dollars. Net cash used.
- Purchases of property, plant and equipment
- negative 20,234,000 US dollars
- Purchases of marketable securities
- negative 365,358,000 US dollars
- Sales and maturities of marketable securities
- 295,489,000 US dollars
- Acquisition of UK Biocentre, net of cash acquired
- negative 11,150,000 US dollars
- Proceeds from other investment
- 0 US dollars
- Net investment hedge settlement
- 0 US dollars
- Deposit received for the sale of B Medical Systems business
- 28,000,000 US dollars
- Financing activities
- negative 51,972,000 US dollars. Net cash used.
- Proceeds from issuance of common stock
- 1,178,000 US dollars
- Payments of finance leases
- negative 583,000 US dollars
- Withholding tax payments on net share settlements on equity awards
- negative 2,521,000 US dollars
- Excise tax payment for settled share repurchases
- 0 US dollars
- Share repurchases
- negative 50,046,000 US dollars
- Operating adjustment reconciliation
- 232,060,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
- financing gross reconciliation
- 53,150,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- investing gross reconciliation
- 396,742,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
- Exchange-rate effect
- negative 2,594,000 US dollars
- Ending cash on Jun 30, 2026
- 204,671,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
- Cash sources and uses
- 332,490,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
- Net cash change
- negative 92,014,000 US dollars. Ending cash minus beginning cash.
- Cash flow / Net income
- Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
- Operating cash flow
- 35,805,000 US dollars. Operating cash flow used in the free cash flow calculation.
- Cash purchases of property, plant and equipment
- 20,234,000 US dollars. These cash purchases are already included in investing activities above.
- Free cash flow
- 15,571,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.
Chart connections
- Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
- Financing contributions meet at a reconciliation junction before connecting to the net cash total.
- Investing contributions meet at a reconciliation junction before connecting to the net cash total.
- Operating reconciliation adjustments are not all independent cash receipts.
- Net loss −$173.77M + net operating adjustments $209.58M = operating cash +$35.81M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
- Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
- The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
- Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 35,805,000 US dollars minus 20,234,000 US dollars equals 15,571,000 US dollars.
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!